Facebook
Linkedin
Twitter
Home
R&D
FINANCE
MANUFACTURING
APPROVALS
SUPPLY CHAIN
LAUNCHES
EVENTS
EVENTS NEWS
EVENT LISTINGS
APPOINTMENTS
Search
Facebook
Linkedin
Twitter
Home
R&D
FINANCE
MANUFACTURING
APPROVALS
SUPPLY CHAIN
LAUNCHES
EVENTS
EVENTS NEWS
EVENT LISTINGS
APPOINTMENTS
Search
Home
Authors
Posts by Dominic Cuthbert
Dominic Cuthbert
49 POSTS
0 COMMENTS
http://www.pbiforum.net
Immusoft and Takeda to develop cell therapies for rare neurometabolic disorders
15th October 2021
CureVac to shift focus of COVID-19 vaccine development to second-gen mRNA...
15th October 2021
Advancing access to complex medicines through Strategic Growth
13th October 2021
Acquisition sees Supernus strengthen CNS product portfolio
13th October 2021
Pacira BioSciences boosts non-opioid pain management position with Flexion acquisition
13th October 2021
Ipsen taps Novartis talent for new Specialty Care International president
12th October 2021
Merck submits EUA in the US for molnupiravir
11th October 2021
Sandoz completes acquisition of GSK’s cephalosporin antibiotics business
11th October 2021
Humanigen signs contract with Clinigen for Lenzilumab Managed Access Program in...
11th October 2021
Entia rases £12m to launch virtual oncology solution
11th October 2021
1
2
3
...
5
Page 1 of 5
News
AbbVie and Xilio Therapeutics to develop novel tumor-activated immunotherapies
14th February 2025
AbbVie and Xilio Therapeutics, a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, have announced a collaboration and...
Duchenne muscular dystrophy market to reach $5.2 billion in 7MM by 2033, forecasts GlobalData
14th February 2025
The Duchenne muscular dystrophy (DMD) market across the seven major markets (7MM*) is set to grow from $2.3 billion in 2023 to $5.2 billion...
Royalty Pharma to provide $250m R&D funding in Biogen lupus collaboration
13th February 2025
Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a...